North American Bladder Cancer Market to Witness Robust Expansion by 2028
North American bladder cancer market is estimated to grow significantly at a CAGR of around 9.6% during the forecast period. Major factors that are augmenting the growth of the North American bladder cancer market include increasing healthcare expenditure, raising awareness of cancer among the population, and surging aging population base coupled with the significant prevalence of bladder cancer across the region. Moreover, the presence of key market players in the region is also augmenting the market growth. Major players that are significantly present in the region are Pfizer, Inc., and Spectrum Pharmaceuticals, Inc.
Get Free Sample link @ https://www.omrglobal.com/request-sample/north-american-bladder-cancer-market
North American bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. Transitional cell bladder cancer is the most common type of bladder cancer. As per the Canadian Cancer Society, it makes up over 90% of all bladder cancers.
A full report of North American Bladder Cancer Market available @ https://www.omrglobal.com/industry-reports/north-american-bladder-cancer-market
· Market Coverage
· Market number available for – 2022-2028
· Base year- 2021
· Forecast period- 2022-2028
· Segment Covered- By Source, By Product Type, By Applications
· Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
North American Bladder Cancer Market by Cancer Type
o Transitional Cell Bladder Cancer/ Urothelial Carcinoma
o Squamous Cell Bladder Cancer
o Adenocarcinoma
o Others (Sarcomas, Carcinoma in Situ)
North American Bladder Cancer Market by Diagnosis
o Cystoscopy
o Biopsy
o Urinalysis
o Urine Cytology
o Intravenous Pyelogram (IVP)
o Others (Biomarkers)
North American Bladder Cancer Market by Treatment
o Surgery
o Chemotherapy
o Immunotherapy
o Radiation Therapy
o Others (Targeted Therapy)
Regional Analysis
o United States
o Canada
Company Profiles
o Astellas Pharma Inc.
o AstraZeneca PLC
o Bayer AG
o Bristol-Myers Squibb Co.
o Eli Lilly and Co.
o EMD Serono, Inc.
o F. Hoffmann-La Roche Ltd.
o Genentech Inc.
o GlaxoSmithKline Plc
o Johnson & Johnson Services, Inc.
o Merck & Co., Inc.
o Pfizer Inc.
o Spectrum Pharmaceuticals, Inc.
o Taris Biomedical LLC
The Report Covers
- Comprehensive research methodology of the North American bladder cancer market.
